Polyethylene glycol microspheres loaded with irinotecan for arterially directed embolic therapy of metastatic liver cancer

Table 1 Baseline patient characteristics

	n	% (range)
Male	28	56
Female	22	44
Age (yr), median	63	(46-86)
Tumor size (mm), median	35	(5-130)
1-2 nodules	15	30
3-5 nodules	18	36
> 5 nodules	17	34
Tumor antigens
Ca 19.9 (U/mL), median baseline	14	(1.9-7628)
Ca 19.9 (U/mL), median 1 mo	10.3	(1.8-1558)
Ca 19.9 (U/mL), median 3 mo	20	(5.8-1234)
Ca 19.9 (U/mL), median 6 mo	85	(2.6-1138)
CEA (U/mL), median baseline	31.1	(0.7-453)
CEA (U/mL), median 1 mo	35	(3-370)
CEA (U/mL), median 3 mo	32.5	(3-1057)
CEA (U/mL), median 6 mo	22.85	(0.5-735)
Previous surgery
Primary tumor resection	48	96
Metastasectomy	17	34
No surgery	2	4

Table 2 Adverse events (G1-G2)

	n (%)
Pain	16 (32)
Transaminase rise	10 (20)
Fever	7 (14)
None	20 (40)